Efficacy and Safety of Huaier and Sorafenib in Treatment of Small Hepatocellular Carcinoma Following Radical Resection_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LEIJian-yong ,  YANLu-nan , ZENGYong , WENTian-fu , LIBo , WANGWen-tao , XUMing-qing , YANGJia-yin , WUHong , WEIYong-gang

Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;

Corresponding?author：

YANLu-nan, Email: yanlunan688@163.com

Keywords：

Huaier; Sorafenib; Hepatocellular carcinoma; Recurrence

DOI：

10.7507/1007-9424.20140238

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To compare the efficacy and safety of Huaier and Sorafenib in treatment of small hepatocellular carcinoma(HCC)following radical resection. Methods Eighty-two patients with small HCC accepted radical liver resection and then taken Huaier or Sorafenib were collected retrospectively. These patients were divided into Huaier group(51 cases)and Sorafenib group(31 cases)according to the different administration drugs after operation. The baseline characteristics, tumor characteristics, survival rate, tumor recurrence rate, and side effects were compared between two groups. Results ①There were no significant differences on the baseline demographic characteristics, liver function, and tumor characteristics between two groups(P > 0.05).②The overall survival rate and tumor-free survival rate had no significant differences between the Huaier group and the Sorafenib group(P=0.737, P=0.699).③The rate of recurrence or metastasis had no significant difference between the Huaier group and Sorafenib group(37.3% versus 32.3%, P=0.648). The most common site of the recurrence or metastasis was the liver and the lung followed.④There were only 5 cases suffered side effects after taking Huaier and no case needed Huaier discontinuance. However, 11 cases suffered side effects after taking Sorafenib and 3 cases needed Sorafenib discontinuance, and the rate of the side effect in the Sorafenib group was much higher than that in the Huaier group(35.5% versus 9.8%, P=0.026). Conclusion For the small HCC who accepted radical liver resection, Huaier seems to be an effective and safe drug.

Citation： LEIJian-yong, YANLu-nan, ZENGYong, WENTian-fu, LIBo, WANGWen-tao, XUMing-qing, YANGJia-yin, WUHong, WEIYong-gang. Efficacy and Safety of Huaier and Sorafenib in Treatment of Small Hepatocellular Carcinoma Following Radical Resection. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(8): 991-995. doi: 10.7507/1007-9424.20140238 Copy

1.	Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancent, 2003, 362(9399): 1907-1917.
2.	Willatt JM, Francis IR, Novelli PM, et al. Interventional therapies for hepatocellular carcinoma[J]. Cancer Imaging, 2012, 12(1): 79-88.
3.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2000[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
4.	Crissien AM, Frenette C. Current management of hepatocellular carcinoma[J]. Gastroenterol Hepatol, 2014, 10(3): 153-161.
5.	莢衛東.根治性肝切除聯合索拉非尼治療肝細胞癌的研究進展[J].世界華人消化雜志, 2012, 20(22): 2019-2023.
6.	劉寶瑞, 王婷婷, 錢曉萍.原發性肝癌分子靶向治療研究進展[J].世界華人消化雜志, 2009, 17(10): 992-997.
7.	張嵐, 任正剛.索拉菲尼治療肝癌常見不良反應及處理的研究進展[J].中國腫瘤臨床, 2013, 40(20): 1268-1271.
8.	吳暉.槐耳顆粒聯合化療栓塞術治療原發性肝癌96例[J].中國藥業, 2014, 23(3): 16-18.
9.	Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J]. J Hepatol, 2003, 38(2): 200-207.
10.	Hasegawa K, Takayama T, Ijichi MA, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial[J]. Hepatology, 2006, 44(4): 891-895.
11.	Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
12.	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phaseⅢrandomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
13.	Gabibbo G, Graxi A. Hepatocellula cancer: optial strategies for screening and surveillance[J]. Dig Dis, 2009, 27(2): 142-147.
14.	於雷, 代智, 周儉, 等.原發性肝癌的分子靶向治療新進展[J].中華肝臟病雜志, 2009, 17(6): 475-477.
15.	程若川, 王建忠.槐耳的研制及臨床應用[J].昆明醫學院學報, 2003, 24(1): 106-110.
16.	李敬東, 彭勇, 戴毅, 等.槐耳顆粒聯合肝動脈灌注化療栓塞治療晚期肝癌的臨床研究[J].西部醫學, 2010, 22(3): 418-420.
17.	許戈良, 莢衛東, 馬金良, 等.槐耳清膏體外抑制血管生成的實驗研究[J].中國藥理學通報, 2003, 19(12): 1410-1412.
18.	莫斌, 楊家印, 嚴律南, 等.槐耳顆粒用于肝癌肝移植術后的臨床觀察[J].四川大學學報:醫學版, 2011, 42(5): 739-741.
19.	劉濤.索拉菲尼治療原發性肝細胞癌的療效及安全性[J].當代醫學, 2013, 19(20): 147-148.
20.	張惠潔, 郭衛東.索拉菲尼在腫瘤治療中的研究進展[J/CD].中華臨床醫師雜志:電子版, 2013, 7(1): 137-139.
21.	Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafinib in patients with hepatocellular carcinoma and ChildPugh A versus B cirrhosis[J]. Gastrointest Cancer Res, 2011, 4(2): 40-44.

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancent, 2003, 362(9399): 1907-1917.
2. Willatt JM, Francis IR, Novelli PM, et al. Interventional therapies for hepatocellular carcinoma[J]. Cancer Imaging, 2012, 12(1): 79-88.
3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2000[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
4. Crissien AM, Frenette C. Current management of hepatocellular carcinoma[J]. Gastroenterol Hepatol, 2014, 10(3): 153-161.
5. 莢衛東.根治性肝切除聯合索拉非尼治療肝細胞癌的研究進展[J].世界華人消化雜志, 2012, 20(22): 2019-2023.
6. 劉寶瑞, 王婷婷, 錢曉萍.原發性肝癌分子靶向治療研究進展[J].世界華人消化雜志, 2009, 17(10): 992-997.
7. 張嵐, 任正剛.索拉菲尼治療肝癌常見不良反應及處理的研究進展[J].中國腫瘤臨床, 2013, 40(20): 1268-1271.
8. 吳暉.槐耳顆粒聯合化療栓塞術治療原發性肝癌96例[J].中國藥業, 2014, 23(3): 16-18.
9. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J]. J Hepatol, 2003, 38(2): 200-207.
10. Hasegawa K, Takayama T, Ijichi MA, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial[J]. Hepatology, 2006, 44(4): 891-895.
11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
12. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phaseⅢrandomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
13. Gabibbo G, Graxi A. Hepatocellula cancer: optial strategies for screening and surveillance[J]. Dig Dis, 2009, 27(2): 142-147.
14. 於雷, 代智, 周儉, 等.原發性肝癌的分子靶向治療新進展[J].中華肝臟病雜志, 2009, 17(6): 475-477.
15. 程若川, 王建忠.槐耳的研制及臨床應用[J].昆明醫學院學報, 2003, 24(1): 106-110.
16. 李敬東, 彭勇, 戴毅, 等.槐耳顆粒聯合肝動脈灌注化療栓塞治療晚期肝癌的臨床研究[J].西部醫學, 2010, 22(3): 418-420.
17. 許戈良, 莢衛東, 馬金良, 等.槐耳清膏體外抑制血管生成的實驗研究[J].中國藥理學通報, 2003, 19(12): 1410-1412.
18. 莫斌, 楊家印, 嚴律南, 等.槐耳顆粒用于肝癌肝移植術后的臨床觀察[J].四川大學學報:醫學版, 2011, 42(5): 739-741.
19. 劉濤.索拉菲尼治療原發性肝細胞癌的療效及安全性[J].當代醫學, 2013, 19(20): 147-148.
20. 張惠潔, 郭衛東.索拉菲尼在腫瘤治療中的研究進展[J/CD].中華臨床醫師雜志:電子版, 2013, 7(1): 137-139.
21. Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafinib in patients with hepatocellular carcinoma and ChildPugh A versus B cirrhosis[J]. Gastrointest Cancer Res, 2011, 4(2): 40-44.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Efficacy and Safety of Huaier and Sorafenib in Treatment of Small Hepatocellular Carcinoma Following Radical Resection

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content